Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9721693.1Aexternal-prioritypatent/GB9721693D0/en
Application filed by Smithkline Beecham PlcfiledCriticalSmithkline Beecham Plc
Publication of NZ522730ApublicationCriticalpatent/NZ522730A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The use of an insulin sensitiser for the manufacture of a medicament for the treatment of hyperglycaemia wherein plasma glucose levels are in the range of from elevated normal to< 126mg/dl. The use wherein the insulin sensitiser is selected from the list consisting of: (+) -5-[[4-[(3,4-dihydro-6_hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidine (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl]-thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiszolidine-2,4-dione (or piolitazone) and 5-[2-benzyl-2,3_dihydrobenzopyran)-5ylmethyl) thiszolidine-2,4-dione (or englitazone); or a tautomeric from thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
NZ522730A1997-10-132002-11-22Use of thiazolidinediones for the treatment of hyperglycaemia
NZ522730A
(en)
Use of the compound 5- [4- [2- (5-ethylpyridin-2-yl) -ethoxy] benzyl] thiazolidine-2,4-dione (pioglitazone) for the manufacture of a medicament for the treatment of impaired glucose tolerance
Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative